Repeatability of ¹⁸F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials.

ABSTRACT:

Background

Standard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients that have bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deoxy-2-[18F]fluoro-D-glucose (¹⁸F-FDG) in a cohort of breast cancer patients with bone-dominant metastases to determine response criteria. The thresholds for 95% specificity of change versus no-change were then applied to a second cohort of breast cancer patients with bone-dominant metastases.

Methods

For this study, nine patients with 38 bone lesions were imaged with ¹⁸F-FDG in the same calibrated scanner twice

SUBMITTER: Muzi M 

PROVIDER: S-EPMC10973316 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature